Your session is about to expire
← Back to Search
Device
Active for Epilepsy (eTNS for DRE Trial)
N/A
Waitlist Available
Research Sponsored by NeuroSigma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age 18-65
Partial onset seizures (complex partial or secondary generalized tonic-clonic)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up four weeks
Awards & highlights
eTNS for DRE Trial Summary
The purpose of this study is to evaluate the tolerability and safety of the NeuroSigma eTNS system.
Eligible Conditions
- Epilepsy
eTNS for DRE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria beloweTNS for DRE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ four weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~four weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety of eTNS
Secondary outcome measures
Beck Depression Inventory
Quality of Life
Skin Irritation
+1 moreeTNS for DRE Trial Design
1Treatment groups
Experimental Treatment
Group I: ActiveExperimental Treatment1 Intervention
Trigeminal nerve stimulation
Find a Location
Who is running the clinical trial?
NeuroSigma, Inc.Lead Sponsor
1 Previous Clinical Trials
25 Total Patients Enrolled
Olive View-UCLA Education & Research InstituteOTHER
33 Previous Clinical Trials
879,994 Total Patients Enrolled
2 Trials studying Epilepsy
200 Patients Enrolled for Epilepsy
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger